Nine complex biological drugs, all of which lack competition or price controls in the United States, accounted for 19 percent of all spending by Kaiser on PEBB members in 2015. The cost of speciality drugs is increasing 27 percent a year. Meanwhile, the board appointed Mark Fairbanks, chief financial officer of the Oregon Health Authority, its new vice-chairman.
Jan 20, 2016